A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, in Combination With Anastrozole in Women With Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Trial Profile

A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 Inhibitor, in Combination With Anastrozole in Women With Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2017

At a glance

  • Drugs Palbociclib (Primary) ; Anastrozole; Goserelin
  • Indications Breast cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms NeoPalAna
  • Most Recent Events

    • 09 Dec 2017 Results assessing Tumor infiltrating lymphocytes as a biomarker for resistance to palbociclib, presented at the 40th Annual San Antonio Breast Cancer Symposium
    • 09 Dec 2017 Results evaluated the utility of a research algorithm for the 70-gene signature (70-GS) in identifying Pal resistant versus sensitive patients, were presented at the 40th Annual San Antonio Breast Cancer Symposium.
    • 10 Jun 2017 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top